With A Potential Blockbuster Alzheimer’s Drug, Is This Ten-Bagger Stock Still A Buy?

With a potential blockbuster drug in its pipeline that would also be the first new therapy for Alzheimer’s disease in decades, the stock featured in today’s article has achieved ten-bagger status in a little over a month. Is it still a buy now? To answer this question, the author looks at both the drug’s blockbuster potential as well as the bearish argument for the stock. For more, CLICK HERE.